NCT06717932View on ClinicalTrials.gov

A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 Injection

Enrolling by invitationOBSERVATIONAL
Enrollment

8

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

November 30, 2039

Study Completion Date

November 30, 2039

Conditions
Beta-Thalassemia
Trial Locations (1)

Unknown

The First Affiliated Hospital of Guangxi Medical University, Nanning

Sponsors
All Listed Sponsors
lead

CorrectSequence Therapeutics Co., Ltd

INDUSTRY